Aclaris Therapeutics, Inc.
ACRS
$3.59
$0.298.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -58.20% | -41.87% | -47.56% | -42.87% | -40.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -58.20% | -41.87% | -47.56% | -42.87% | -40.09% |
| Cost of Revenue | 24.16% | 1.63% | -36.49% | -49.22% | -56.14% |
| Gross Profit | -73.28% | -36.92% | 29.84% | 52.03% | 62.18% |
| SG&A Expenses | -1.04% | -13.08% | -14.88% | -27.29% | -29.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.95% | -5.32% | -32.40% | -45.09% | -51.12% |
| Operating Income | -41.03% | -11.44% | 26.28% | 45.78% | 54.13% |
| Income Before Tax | 50.84% | -279.12% | -128.05% | -67.73% | -48.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 50.84% | -282.88% | -129.47% | -68.53% | -49.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.84% | -282.88% | -129.47% | -68.53% | -49.26% |
| EBIT | -41.03% | -11.44% | 26.28% | 45.78% | 54.13% |
| EBITDA | -41.71% | -12.00% | 26.10% | 45.70% | 54.17% |
| EPS Basic | 64.96% | -165.78% | -65.55% | -28.01% | -18.68% |
| Normalized Basic EPS | 8.80% | 33.67% | 55.54% | 62.57% | 63.20% |
| EPS Diluted | 64.96% | -165.78% | -65.55% | -28.01% | -18.68% |
| Normalized Diluted EPS | 8.80% | 33.67% | 55.54% | 62.57% | 63.20% |
| Average Basic Shares Outstanding | 58.63% | 62.64% | 44.93% | 27.17% | 10.70% |
| Average Diluted Shares Outstanding | 58.63% | 62.64% | 44.93% | 27.17% | 10.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |